Dianthus Therapeutics Inc.
Ownership
Ownership Structure
Who owns Dianthus Therapeutics Inc. (DNTH)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.9% of the shares are freely tradable; institutional investors hold 120.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.89 | 7,767,686 | +20.8 | 03/31/2026 |
| Wellington Management Company LLP | 5.77 | 3,229,882 | +24.4 | 06/30/2026 |
| BlackRock Inc | 5.68 | 3,175,703 | +65.8 | 03/31/2026 |
| RA Capital Management, LLC | 4.67 | 2,611,733 | +62.0 | 03/31/2026 |
| Fairmount Funds Management LLC | 4.54 | 2,537,191 | +18.7 | 03/31/2026 |
| Avidity Partners Management LP | 3.76 | 2,104,184 | -50.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.63 | 2,031,249 | +0.0 | 03/31/2026 |
| Octagon Capital Advisors LP | 3.29 | 1,841,667 | -5.4 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 3.94 | 2,203,420 | +0.0 | 07/31/2026 |
| T. Rowe Price Capital Appreciation | 3.14 | 1,758,357 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Garcia Marino | CEO AND PRESIDENT | 65,292 | 6,601,021 $ | Aug 7, 2026 | direct |
| Veness Adam M | SVP, General Counsel and Sec. | 15,000 | 1,516,500 $ | Aug 13, 2026 | direct |
| Randhawa Simrat | EVP, Head of R&D | 4,000 | 404,400 $ | Sep 1, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Sell | 13,309 | 106.74 | 1,420,603 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Sell | 7,215 | 106.25 | 766,594 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Sell | 2,600 | 105.19 | 273,494 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Other | 9,375 | 22.07 | 206,906 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Other | 6,249 | 21.77 | 136,041 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | Other | 7,500 | 17.88 | 134,100 |
| Aug 19, 2026 | Read Simon | Director | Sell | 2,778 | 117.55 | 326,554 |
| Aug 19, 2026 | Read Simon | Director | Other | 2,778 | 18.36 | 51,004 |
| Aug 13, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Other | 15,000 | 18.17 | 272,550 |
| Aug 10, 2026 | McGeorge Anne | Director | Sell | 700 | 111.41 | 77,987 |
| Aug 10, 2026 | McGeorge Anne | Director | Sell | 1,000 | 110.64 | 110,640 |
| Aug 10, 2026 | McGeorge Anne | Director | Sell | 1,800 | 109.30 | 196,740 |
| Aug 10, 2026 | McGeorge Anne | Director | Sell | 2,800 | 108.38 | 303,464 |
| Aug 10, 2026 | McGeorge Anne | Director | Sell | 1,450 | 107.58 | 155,991 |
| Aug 10, 2026 | McGeorge Anne | Director | Other | 6,500 | 11.20 | 72,800 |
| Aug 10, 2026 | McGeorge Anne | Director | Other | 1,250 | 19.36 | 24,200 |
| Aug 10, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 16,167 | 110.38 | 1,784,513 |
| Aug 10, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Other | 16,167 | 17.88 | 289,066 |
| Aug 10, 2026 | Read Simon | Director | Sell | 397 | 111.77 | 44,373 |
| Aug 10, 2026 | Read Simon | Director | Sell | 470 | 111.05 | 52,194 |
| Aug 10, 2026 | Read Simon | Director | Sell | 272 | 109.96 | 29,909 |
| Aug 10, 2026 | Read Simon | Director | Sell | 831 | 108.95 | 90,537 |
| Aug 10, 2026 | Read Simon | Director | Sell | 737 | 108.17 | 79,721 |
| Aug 10, 2026 | Read Simon | Director | Sell | 70 | 107.11 | 7,498 |
| Aug 10, 2026 | Read Simon | Director | Other | 2,777 | 18.36 | 50,986 |
| Aug 7, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 616 | 111.18 | 68,487 |
| Aug 7, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 3,217 | 110.61 | 355,832 |
| Aug 7, 2026 | Veness Adam M | SVP, General Counsel and Sec. | Other | 3,833 | 17.88 | 68,534 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 21,909 | 108.72 | 2,381,946 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 104,091 | 107.96 | 11,237,664 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 800 | 110.76 | 88,608 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 2,536 | 110.02 | 279,011 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 2,373 | 109.10 | 258,894 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 23,907 | 108.05 | 2,583,151 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Sell | 10,384 | 107.49 | 1,116,176 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Other | 126,000 | 8.44 | 1,063,440 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | Other | 40,000 | 8.44 | 337,600 |
| Jul 9, 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | 5,566 | 101.97 | 567,565 |
| Jul 9, 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | 15,329 | 101.24 | 1,551,908 |
| Jul 9, 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | 10,354 | 100.22 | 1,037,678 |
| Jul 9, 2026 | Savitz Ryan | EVP, CFO & CBO | Other | 31,249 | 21.77 | 680,291 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.